These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26958930)

  • 1. Bacteriophage Therapy: Advances in Formulation Strategies and Human Clinical Trials.
    Vandenheuvel D; Lavigne R; Brüssow H
    Annu Rev Virol; 2015 Nov; 2(1):599-618. PubMed ID: 26958930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections.
    Semler DD; Lynch KH; Dennis JJ
    Front Cell Infect Microbiol; 2011; 1():27. PubMed ID: 22919592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DRUG DEVELOPMENT. Beleaguered phage therapy trial presses on.
    Servick K
    Science; 2016 Jun; 352(6293):1506. PubMed ID: 27339963
    [No Abstract]   [Full Text] [Related]  

  • 5. Hurdles in bacteriophage therapy: deconstructing the parameters.
    Tsonos J; Vandenheuvel D; Briers Y; De Greve H; Hernalsteens JP; Lavigne R
    Vet Microbiol; 2014 Jul; 171(3-4):460-9. PubMed ID: 24315040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phage cocktails and the future of phage therapy.
    Chan BK; Abedon ST; Loc-Carrillo C
    Future Microbiol; 2013 Jun; 8(6):769-83. PubMed ID: 23701332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
    Ryan EM; Gorman SP; Donnelly RF; Gilmore BF
    J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phage therapy gets revitalized.
    Reardon S
    Nature; 2014 Jun; 510(7503):15-6. PubMed ID: 24899282
    [No Abstract]   [Full Text] [Related]  

  • 9. Turning a new phage.
    Gravitz L
    Nat Med; 2012 Sep; 18(9):1318-20. PubMed ID: 22961150
    [No Abstract]   [Full Text] [Related]  

  • 10. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting phage therapy: new applications for old resources.
    Nobrega FL; Costa AR; Kluskens LD; Azeredo J
    Trends Microbiol; 2015 Apr; 23(4):185-91. PubMed ID: 25708933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteriophage therapy for safeguarding animal and human health: a review.
    Tiwari R; Dhama K; Kumar A; Rahal A; Kapoor S
    Pak J Biol Sci; 2014 Feb; 17(3):301-15. PubMed ID: 24897784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial bioagents based on principles of bacteriophage biology: an overview.
    Knoll BM; Mylonakis E
    Clin Infect Dis; 2014 Feb; 58(4):528-34. PubMed ID: 24270166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotechnological exploitation of bacteriophage research.
    Petty NK; Evans TJ; Fineran PC; Salmond GP
    Trends Biotechnol; 2007 Jan; 25(1):7-15. PubMed ID: 17113664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phage therapy for plant disease control.
    Balogh B; Jones JB; Iriarte FB; Momol MT
    Curr Pharm Biotechnol; 2010 Jan; 11(1):48-57. PubMed ID: 20214607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria.
    Brown TL; Thomas T; Odgers J; Petrovski S; Spark MJ; Tucci J
    J Pharm Pharmacol; 2017 Mar; 69(3):244-253. PubMed ID: 28033675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respirable bacteriophages for the treatment of bacterial lung infections.
    Hoe S; Semler DD; Goudie AD; Lynch KH; Matinkhoo S; Finlay WH; Dennis JJ; Vehring R
    J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):317-35. PubMed ID: 23597003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European regulatory conundrum of phage therapy.
    Verbeken G; De Vos D; Vaneechoutte M; Merabishvili M; Zizi M; Pirnay JP
    Future Microbiol; 2007 Oct; 2(5):485-91. PubMed ID: 17927471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects.
    McCallin S; Alam Sarker S; Barretto C; Sultana S; Berger B; Huq S; Krause L; Bibiloni R; Schmitt B; Reuteler G; Brüssow H
    Virology; 2013 Sep; 443(2):187-96. PubMed ID: 23755967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-establishing a place for phage therapy in western medicine.
    Kutter EM; Kuhl SJ; Abedon ST
    Future Microbiol; 2015; 10(5):685-8. PubMed ID: 26000644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.